McCormick and DeLauro Introduce CLEAR LABELS Act to Track Drug Ingredients
The CLEAR LABELS Act was recently introduced in the House and is currently being reviewed by two committees. It is in the early stages of the legislative process and is not yet scheduled for a vote. The bill is actively moving through the initial committee review phase.
Part of: story →The bill has support from both parties, which helps its chances. However, many bills like this struggle to get a full vote in the House and Senate before the session ends.
Small pharmaceutical companies, independent pharmacies that repackage drugs, and small distributors would face new compliance costs to update labeling, create electronic portals, and track supply chain information. While the bill allows QR codes and electronic alternatives that reduce physical labeling burden, the administrative effort to identify and verify original manufacturers could be costly for smaller players.
“A manufacturer, packer, or distributor required to furnish information under subparagraphs (1), (2), and (3), in addition to making such information available electronically, as applicable, shall make such information available through a package insert, or in paper copy to any individual who requests such a copy.”
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
No votes have been recorded for this legislation yet.
Representatives Rich McCormick and Rosa DeLauro introduced the bipartisan CLEAR LABELS Act in the House. The bill requires drug labels to list original manufacturers of both drugs and active ingredients, allowing for digital formats like QR codes while ensuring consumer transparency.
The CLEAR LABELS Act proposes requiring drug companies to disclose manufacturing locations for generic drugs and APIs. The bill suggests using QR codes on packaging to link to a searchable database with manufacturing details and drug quality scores.
Sen. Katie Britt joined colleagues in introducing the CLEAR LABELS Act, which would require drug labels to disclose original manufacturers. The bill aims to provide patients and providers with clear information about where their medications are produced.
Document Type
Congressional Bill
Official Title
CLEAR LABELS Act
Analysis generated by AI. Always verify with official sources.